Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 1/20 | 0.34 |
| ▸ | PEPD | P12955 | 2/20 | 0.33 |
| ▸ | XPNPEP1 | Q9NQW7 | 1/20 | 0.32 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.32 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.32 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.32 |
| ▸ | MMP2 | P08253 | 1/20 | 0.30 |
| ▸ | ANPEP | P15144 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18009194 | 0.91 | PEPD (0.39) | PIK3CDPEPDXPNPEP1KEAP1NFE2L2 | |
| SCHEMBL18009337 | 0.89 | MMP2 (0.42) | KEAP1NFE2L2HCAR2MMP2ANPEP | |
| SCHEMBL18009192 | 0.86 | PIK3CD (0.36) | PIK3CDKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009388 | 0.86 | PEPD (0.34) | PIK3CDPEPDXPNPEP1KEAP1NFE2L2 | |
| SCHEMBL18009375 | 0.86 | PIK3CD (0.33) | PIK3CDPEPDXPNPEP1KEAP1NFE2L2 | |
| SCHEMBL18007441 | 0.85 | PIN1 (0.35) | PIK3CDPEPDXPNPEP1KEAP1NFE2L2 | |
| SCHEMBL18009295 | 0.83 | PIK3CD (0.34) | PIK3CDKEAP1NFE2L2HCAR2 | |
| SCHEMBL18009287 | 0.81 | SLC6A3 (0.37) | MMP2 | |
| SCHEMBL18009300 | 0.81 | PIK3CD (0.42) | PIK3CDMMP2 | |
| SCHEMBL18007434 | 0.81 | HCAR2 (0.38) | HCAR2MMP2ANPEP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016127186-A1 | FUMARATE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS THEREOF, AND METHODS OF USE | NGUYEN MARK QUANG (US) | 2016-08-11 | — | — | WO | disclosed |